Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis

ABSTRACT Literature reports that lncRNA KCNQ1OT1 is markedly up-regulated in cervical cancer (CC) tissues and cell lines, and KCNQ1OT1 can promote the proliferation and metastasis of CC cells. This current work was designed to investigate the molecular mechanism underlying the participation of KCNQ1OT1 in CC progression. Herein, RT-qPCR was utilized for determining the levels of KCNQ1OT1, miR-296-5p and HYOU1 in clinical tumor tissue specimens and CC cell lines. Then, starBase predicted the complementary binding sites of KCNQ1OT1 and miR-296-5p or miR-296-5p and HYOU1. Dual-luciferase reporter assay/RIP assay validated the interplays among KCNQ1OT1/miR-296-5p/HYOU1. In addition, CCK-8, wound healing and transwell assays were employed to assess the proliferative, migrative and invasive properties of CC cells. Moreover, nude mice xenograft model was established by subcutaneously injection with SiHa cells in order to validate the precise functions of KCNQ1OT1/miR-296-5p/HYOU1 axis in CC in vivo. Besides, Immunohistochemical staining examined Ki-67 expression in xenograft tumors and western blotting analysis detected expressions of MMP2/9 and Wnt/β-catenin signaling pathway in CC cells and xenograft tumors. Elevated KCNQ1OT1 and HYOU1 as well as reduced miR-296-5p were observed in clinical tumor tissue specimens and CC cell lines. Results revealed that upregulation of miR-296-5p counteracted the enhancing effects of overexpressed KCNQ1OT1 on the proliferative, migrative and invasive abilities of CC cells. Additionally, HYOU1 overexpression abolished the suppressing effects of silenced KCNQ1OT1 on the malignant behaviors of CC cells and tumor growth. To conclude, KCNQ1OT1 could aggravate the malignant behaviors of CC and facilitate tumor growth through modulating miR-296-5p/HYOU1 axis.

[1]  Shanshan Yang,et al.  Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data , 2021, Frontiers in Cell and Developmental Biology.

[2]  H. Nishi,et al.  Circulating and tissue miR-100 acts as a potential diagnostic biomarker for cervical cancer. , 2021, Cancer biomarkers : section A of Disease markers.

[3]  P. Zhou,et al.  Circular RNA hsa_circ_0000511 Improves Epithelial Mesenchymal Transition of Cervical Cancer by Regulating hsa-mir-296-5p/HMGA1 , 2021, Journal of immunology research.

[4]  H. Zhang,et al.  KCNQ1 opposite strand/antisense transcript 1 promotes aggressive biological behaviors of cervical cancer cells via regulating microRNA-491-5p and pyruvate kinase M1/2. , 2020, Journal of Biological Regulators and Homeostatic Agents.

[5]  Y. Ai,et al.  Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2–IIIB cervical adenocarcinoma , 2020, Archives of Gynecology and Obstetrics.

[6]  E. C. Coimbra,et al.  Long noncoding RNAs (lncRNAs) in cervical carcinogenesis: New molecular targets, current prospects. , 2020, Critical reviews in oncology/hematology.

[7]  G. Lou,et al.  SP1‐induced lncRNA FOXD3‐AS1 contributes to tumorigenesis of cervical cancer by modulating the miR‐296‐5p/HMGA1 pathway , 2020, Journal of cellular biochemistry.

[8]  Chun Qiu,et al.  LncRNA MSC-AS1 facilitates lung adenocarcinoma through sponging miR-33b-5p to up-regulate GPAM. , 2020, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[9]  Yili Liu,et al.  LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by targeting MiR-218-5p/HS3ST3B1 , 2020, Cancer Gene Therapy.

[10]  Lin Li,et al.  LncRNA KCNQ1OT1 regulates the invasion and migration of hepatocellular carcinoma by acting on S1PR1 through miR-149 , 2020, Cancer Gene Therapy.

[11]  Kun Zhang,et al.  Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  Xiang Yu,et al.  lncRNA KCNQ1OT1 knockdown inhibits colorectal cancer cell proliferation, migration and invasiveness via the PI3K/AKT pathway , 2020, Oncology letters.

[13]  Yan Wang,et al.  LncRNA KCNQ1OT1 promotes cell proliferation, migration and invasion via regulating miR-129-5p/JAG1 axis in non-small cell lung cancer , 2020, Cancer Cell International.

[14]  Young Seok Kim,et al.  Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy. , 2020, Gynecologic oncology.

[15]  Ningjing Lei,et al.  Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway , 2020, Cancer Cell International.

[16]  F. Buonaguro,et al.  The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer , 2020, Frontiers in Oncology.

[17]  Xueyuan Liu,et al.  Long noncoding RNA KCNQ1OT1 promotes apoptosis in neuroblastoma cells by regulating miR‐296‐5p/Bax axis , 2020, The FEBS journal.

[18]  P. Benedetti Panici,et al.  Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition? , 2020, Journal of cellular physiology.

[19]  Weixin Zheng,et al.  Long non-coding RNA SNHG3 accelerates progression in glioma by modulating miR-384/HDGF axis , 2020, Open life sciences.

[20]  Y. Miao,et al.  MicroRNA-296 functions as a tumor suppressor in breast cancer by targeting FGFR1 and regulating the Wnt/β-catenin signaling pathway. , 2019, European review for medical and pharmacological sciences.

[21]  H. Jin,et al.  Effects of LncRNA KCNQ1OT1 on proliferation and migration of ovarian cancer cells by Wnt/β-catenin. , 2019, European Review for Medical and Pharmacological Sciences.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  Xiaodong Wang,et al.  MicroRNA-296 Targets Specificity Protein 1 to Suppress Cell Proliferation and Invasion in Cervical Cancer , 2018, Oncology research.

[24]  Xiaomeng Xia,et al.  Wnt signaling in cervical cancer? , 2018, Journal of Cancer.

[25]  Lei Xu,et al.  LncRNA KCNQ1OT1 promotes osteogenic differentiation to relieve osteolysis via Wnt/β-catenin activation , 2018, Cell & Bioscience.

[26]  O. Sheils,et al.  miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. , 2017, Human pathology.

[27]  A. Avan,et al.  Clinical Significance and Prognosis Value of Wnt Signaling Pathway in Cervical Cancer , 2017, Journal of cellular biochemistry.

[28]  Zhuo-wei Hu,et al.  The regulation of β-catenin activity and function in cancer: therapeutic opportunities , 2017, Oncotarget.

[29]  Z. Zeng,et al.  HYOU1, Regulated by LPLUNC1, Is Up-Regulated in Nasopharyngeal Carcinoma and Associated with Poor Prognosis , 2016, Journal of Cancer.

[30]  M. Frumovitz,et al.  Challenges in the diagnosis and management of cervical neuroendocrine carcinoma , 2015, Expert review of anticancer therapy.

[31]  J. Berumen,et al.  Targeting CDKN3 in cervical cancer , 2014, Expert opinion on therapeutic targets.

[32]  M. B. Major,et al.  Modulation of Kaposi's Sarcoma-Associated Herpesvirus Interleukin-6 Function by Hypoxia-Upregulated Protein 1 , 2014, Journal of Virology.

[33]  A. Stojadinovic,et al.  HYOU1/Orp150 expression in breast cancer. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[34]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[35]  Xiaohong Yu,et al.  MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/β-catenin pathway. , 2019, International journal of clinical and experimental pathology.

[36]  X. Li,et al.  HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. , 2019, European review for medical and pharmacological sciences.